2.41
+0.06(+2.55%)
Currency In USD
| Previous Close | 2.35 |
| Open | 2.36 |
| Day High | 2.51 |
| Day Low | 2.28 |
| 52-Week High | 6.06 |
| 52-Week Low | 1.31 |
| Volume | 164,787 |
| Average Volume | 211,429 |
| Market Cap | 112.48M |
| PE | -1.16 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.99 |
| Moving Average 200 Days | 2.76 |
| Change | 0.06 |
If you invested $1000 in Vigil Neuroscience, Inc. (VIGL) since IPO date, it would be worth $190.51 as of May 09, 2025 at a share price of $2.41. Whereas If you bought $1000 worth of Vigil Neuroscience, Inc. (VIGL) shares 2 years ago, it would be worth $255.3 as of May 09, 2025 at a share price of $2.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLO
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
GlobeNewswire Inc.
Apr 02, 2025 11:00 AM GMT
- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) -
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
GlobeNewswire Inc.
Mar 11, 2025 11:00 AM GMT
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced tha